Agios Pharmaceuticals Inc AGIO
News
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorder